Advertisement
In The News
American Society of Hematology 2016 Annual Meeting

Session 731. Clinical Autologous Transplantation: Results: Clinical Autologous Transplantation in Myeloma I

American Society of Hematology 2016 Annual Meeting

Session 653. Myeloma: Therapy, excluding Transplantation: IMiD/Proteasome Inhibitor Combinations and Maintenance Therapy

American Society of Hematology 2016 Annual Meeting

Abstract 1143: Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study

American Society of Hematology 2016 Annual Meeting

Abstract 673: Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial)

American Society of Hematology 2016 Annual Meeting

Abstract 537: Health-Related Quality of Life of Patients with Newly Diagnosed Multiple Myeloma Receiving Any or Lenalidomide Maintenance after Autologous Stem Cell Transplant in the Connect® MM Disease Registry

The ASCO Post

ESMO 2016 Abstract 55PD: Vemurafenib (VM) in non-melanoma V600 and non-V600 BRAF mutated cancers: First results of the ACSE trial

ESMO

ESMO 2016 Abstract 940TiP - Pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM): randomized, phase 3 KEYNOTE-185 study

ESMO

ESMO 2016 Abstract 941TiP - Pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM): Randomized, phase 3 KEYNOTE-183 study

ESMO

ESMO 2016 Abstract 906O - Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR

The ASCO Post

Study Finds Statin Use Associated With Reduced Mortality in Multiple Myeloma

The ASCO Post

Meta-Analysis Shows Association of Minimal Residual Disease–Negative Status With Improved Survival in Multiple Myeloma

Janssen

Janssen Submits Application to U.S. FDA to Expand Indication for Daratumumab (DARZALEX®)

The ASCO Post

Adding Daratumumab to Bortezomib/Dexamethasone Improves Progression-Free Survival in Relapsed/Refractory Multiple Myeloma

The ASCO Post

Autologous Stem Cell Transplant May Age Immune Cells as Much as 30 Years

ASCO

2016 ASCO Annual Meeting Abstract 8010: Pembrolizumab in Combination With Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Final Efficacy and Safety Analysis

The ASCO Post

FDA Grants Breakthrough Therapy Designation for Daratumumab in Combination With Standard of Care for Multiple Myeloma

ASCO

2016 ASCO Annual Meeting Abstract 8059: Healthcare Costs Among Multiple Myeloma (MM) Patients (Pts) Without Stem Cell Transplant (SCT)

ASCO

2016 ASCO Annual Meeting Abstract 6517: Patients´ Competence in Oral Cancer Therapies

ASCO

2016 ASCO Annual Meeting Abstract 8007: Phase 1/2 Study of Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM): A Multiple Myeloma Research Consortium Multicenter Study

ASCO

2016 ASCO Annual Meeting Abstract 8001: Lenalidomide (LEN) Maintenance (MNTC) After High-Dose Melphalan and Autologous Stem Cell Transplant (ASCT) in Multiple Myeloma (MM): A Meta-Analysis (MA) of Overall Survival (OS)

ASCO

2016 ASCO Annual Meeting Abstract LBA4: Phase III Randomized Controlled Study of Daratumumab, Bortezomib, and Dexamethasone (DVd) Versus Bortezomib and Dexamethasone (Vd) in Patients (Pts) With Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR Study

The ASCO Post

Michele Cavo, MD, on Multiple Myeloma: Results From a European Myeloma Network Trial

The ASCO Post

Kenneth Anderson, MD, on Multiple Myeloma Guideline Updates

The ASCO Post

Sagar Lonial, MD, and Paul G. Richardson, MD, on Multiple Myeloma

The ASCO Post

Antonio Palumbo, MD, on Multiple Myeloma: Results From the CASTOR Trial

The ASCO Post

Adding Daratumumab to Bortezomib and Dexamethasone Markedly Improves Outcomes in Recurrent/Refractory Multiple Myeloma

The ASCO Post

Expert Point of View: Paul G. Richardson, MD

The ASCO Post

Benefits and Risks of Transplantation: The Changing Therapeutic Paradigm for Multiple Myeloma: A Conversation With Paul G. Richardson, MD

The ASCO Post

Study Links Radon Exposure to Increased Risk of Hematologic Malignancies in Women

The ASCO Post

Tight Junction Protein 1 May Identify Sensitivity to Proteasome Inhibitors in Patients With Multiple Myeloma

Reuters

Independent Group Finds Multiple Myeloma Drugs Too Costly in US

The ASCO Post

Geriatric Assessment of Transplant-Ineligible Older Adults With Multiple Myeloma: A Novel Approach in the Era of Novel Agents

The ASCO Post

Carfilzomib Plus Dexamethasone in Previously Treated Multiple Myeloma

The ASCO Post

CAR-T Cell Therapy May Have a Role in Treating Multiple Myeloma

ScienceDaily

New Therapeutic Target in Myeloma Discovered

The ASCO Post

FDA Approves Carfilzomib as Single Agent or in Combination in Relapsed/Refractory Multiple Myeloma

The ASCO Post

Studies Confirm and Extend the Benefits of Ixazomib in Multiple Myeloma

The ASCO Post

Study Confirms Benefit of Triplet vs Doublet in Newly Diagnosed Multiple Myeloma

The ASCO Post

Elotuzumab in Previously Treated Multiple Myeloma

The ASCO Post

Multiple Myeloma in 2015: A Year for the Record Books

Blood

Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma Without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777

Blood

Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up

The ASCO Post

ASH 2015: Updated Results of the Phase I/II GEN503 Study of Daratumumab in Multiple Myeloma

The ASCO Post

Better Quality of Life With Melphalan and Prednisone Used With Lenalidomide Than With Thalidomide

The ASCO Post

Impressive Results With Daratumumab Plus Lenalidomide/Dexamethasone in Multiple Myeloma

Myeloma UK

Highlights from the 15th International Myeloma Workshop

The ASCO Post

FDA Accepts for Priority Review the Biologics License Application for Elotuzumab for the Treatment of Relapsed Multiple Myeloma

The ASCO Post

MMRF Announces Enrollment Completion of CoMMpass Study

The ASCO Post

NCCN Unveils Graphic Evidence Blocks to Guide Decision-Making

The ASCO Post

FDA Approves Daratumumab for Patients With Previously Treated Multiple Myeloma